
Publication
ESG and internal investigations: New compliance challenges
As ESG concerns have come to the forefront in different jurisdictions, the scope of these inquiries is expanding in kind.
Publication | July 2024
The Department of Justice (DOJ) recently announced another of its annual healthcare fraud “takedowns.” Consistent with previous takedowns, this year’s announcement touts criminal charges against 193 individuals (76 of whom are providers) and a massive amount of fraudulent billings (approximately US$2.75 billion). This annual “shock-and-awe” enforcement spectacle reinforces the government’s focus on combatting healthcare fraud … and Texas remains a major focal point for these efforts.
DOJ’s annual takedown press releases provide insight into the Department’s current healthcare fraud enforcement priorities. Not surprisingly, diversion of opioids and other controlled substances remains a major focus. Additionally, services that were medically unnecessary, unduly expensive, tainted by kickbacks or simply not provided were common aspects of the fraudulent schemes. Labs and telemedicine also continue to draw law enforcement scrutiny.
The DOJ’s press release reinforces law enforcement’s continued commitment to inter-agency collaboration and includes accolades for the many different federal and state law enforcement agencies that worked together to develop these cases. Importantly, in addition to the criminal charges mentioned, the press release also references 127 administrative actions taken by the Centers for Medicare & Medicaid Services (CMS) in the last six months against providers for their alleged involvement in health care fraud schemes. And, do not forget that the DOJ persistently remarks that the civil False Claims Act (and its qui tam whistleblower provisions) remain one of its main fraud enforcement tools as well. In short, the blurred lines between federal, state, civil, administrative and criminal enforcement teams are increasingly hazy … and dangerous for providers.
Norton Rose Fulbright’s experienced Healthcare Investigations team represents businesses and executives in government investigations. If you find yourself involved in a government investigation, or if you receive a government subpoena or civil investigative demand (CID), our team will defend your interests aggressively and effectively. Please let us know how what we can do to help.
Publication
As ESG concerns have come to the forefront in different jurisdictions, the scope of these inquiries is expanding in kind.
Publication
In compliance with the constitutional reforms published in the Federal Official Gazette, new secondary legislation regulating the energy sector, specifically in terms of power and hydrocarbons, was published on March 18, 2025.
Publication
On February 1, US President Donald Trump signed three executive orders which impose tariffs on Canada, China, and Mexico based on declared national emergencies associated with purported illegal immigration and fentanyl imports from each country.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025